האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - paklitaksel - breast neoplasms; pancreatic neoplasms; carcinoma, non-small-cell lung - antineoplastična sredstva - monoterapija abraxane je indicirana za zdravljenje metastatskega raka dojk pri odraslih bolnikih, ki niso opravili prve linije za metastatsko bolezen in za katere standardno zdravljenje z antraciklinom ni indicirano. abraxane v kombinaciji z gemcitabine je določen za prvo linijo zdravljenja odraslih bolnikih z metastatskim adenokarcinom trebušne slinavke. abraxane v kombinaciji z carboplatin je določen za prvo linijo zdravljenja non-small cell lung cancer pri odraslih bolnikih, ki niso kandidati za potencialno kurativno operacijo in/ali obsevanjem.

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - pomalidomide - multiple myeloma - imunosupresivi - imnovid v kombinaciji z bortezomib in dexamethasone je indiciran za zdravljenje odraslih bolnikov z več plazmocitom, ki so prejeli vsaj eno predhodno zdravljenje režim, vključno z lenalidomide. imnovid v kombinaciji z deksametazon je indicirano za zdravljenje odraslih bolnikov s ponovila in ognjevarnih multipli mielom, ki so prejeli vsaj dve režimi predhodne obdelave, vključno s lenalidomid in bortezomib, in so pokazali napredovanje bolezni na zadnje terapije.

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

reckitt benckiser d.o.o. - kalcijev karbonat; natrijev alginat; natrijev hidrogenkarbonat - žvečljiva tableta - kalcijev karbonat 80 mg / 1 tableta  natrijev alginat250 mg / 1 tableta  natrijev hidrogenkarbonat133,5 mg / 1 tableta; natrijev alginat 250 mg / 1 tableta  natrijev hidrogenkarbonat133,5 mg / 1 tableta; natrijev hidrogenkarbonat 133,5 mg / 1 tableta - alginska kislina

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

reckitt benckiser d.o.o. - kalcijev karbonat; natrijev alginat; natrijev hidrogenkarbonat - peroralna suspenzija - kalcijev karbonat 16 mg / 1 ml  natrijev alginat50 mg / 1 ml  natrijev hidrogenkarbonat26,7 mg / 1 ml; natrijev alginat 50 mg / 1 ml  natrijev hidrogenkarbonat26,7 mg / 1 ml; natrijev hidrogenkarbonat 26,7 mg / 1 ml - alginska kislina

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

reckitt benckiser d.o.o. - kalcijev karbonat; natrijev alginat; natrijev hidrogenkarbonat - peroralna suspenzija - kalcijev karbonat 16 mg / 1 ml  natrijev alginat50 mg / 1 ml  natrijev hidrogenkarbonat26,7 mg / 1 ml; natrijev alginat 50 mg / 1 ml  natrijev hidrogenkarbonat26,7 mg / 1 ml; natrijev hidrogenkarbonat 26,7 mg / 1 ml - alginska kislina

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

reckitt benckiser healthcare (uk) ltd - kalcijev karbonat; natrijev alginat; natrijev hidrogenkarbonat - peroralna suspenzija - kalcijev karbonat 160 mg / 10 ml  natrijev alginat500 mg / 10 ml  natrijev hidrogenkarbonat267 mg / 10 ml; natrijev alginat 500 mg / 10 ml  natrijev hidrogenkarbonat267 mg / 10 ml; natrijev hidrogenkarbonat 267 mg / 10 ml - alginska kislina

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

reckitt benckiser d.o.o. - kalcijev karbonat; natrijev alginat; natrijev hidrogenkarbonat - žvečljiva tableta - kalcijev karbonat 80 mg / 1 tableta  natrijev alginat250 mg / 1 tableta  natrijev hidrogenkarbonat133,5 mg / 1 tableta; natrijev alginat 250 mg / 1 tableta  natrijev hidrogenkarbonat133,5 mg / 1 tableta; natrijev hidrogenkarbonat 133,5 mg / 1 tableta - alginska kislina

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastična sredstva - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 in 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastična sredstva - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.